The Visual Decision Making Process as a Technique for Redistributing Outdoor Recreation Use

The demand for recreation on public lands has been growing steadily, resulting in undesirable impacts on certain resources as well as recreation experiences. The problem addressed by this research is the uneven distribution of recreational use that causes a concentration of impacts. This thesis describes the development and testing of a method to reduce the uneven/concentrated recreation use occurring on the public lands. The basic objectives of the study were to determine the effectiveness of redistributing recreationists by the use of photographs and a decisional process using photographic information and to identify its potential as a tool in meeting management objectives. The experimental treatment device was the Visual Decision Making Process consisting of color photographs, a map and a selection matrix used in the decision-tree to match people to places that would best suit their needs. Recreationists were surveyed on three different weekends during the spring season of 1980 in the San Rafael Swell of southeastern Utah. People who had been contacted during that time were randomly assigned to treatment or no-treatment control groups. A home interview was conducted prior to the 1981 spring recreation season. After the season, both the treatment and no-treatment control groups were contacted for posttest questioning. Data were collected from the contact questioning, observation, and posttest questionnaires. The results indicated that recreation use was influenced by the Visual Decision Making Process, but only a small percentage of people who went through the process went to an area they chose. While the major influence of the process was not significantly proven, there seemed to be a trend in change behavior. This small percentage of change may be an adequate amount to meet management objectives of lessening impacts. It was also found that persons driving four-wheel drive vehicles and larger groups were significantly more influenced to redistribute than car/pickup drivers and smaller groups. Recommendations are made for management practices to reduce uneven/ concentrated recreation use and suggestions for further research are offered

H3K56me3 is a novel, conserved heterochromatic mark that largely but not completely overlaps with H3K9me3 in both regulation and localization.

Histone lysine (K) methylation has been shown to play a fundamental role in modulating chromatin architecture and regulation of gene expression. Here we report on the identification of histone H3K56, located at the pivotal, nucleosome DNA entry/exit point, as a novel methylation site that is evolutionary conserved. We identify trimethylation of H3K56 (H3K56me3) as a modification that is present during all cell cycle phases, with the exception of S-phase, where it is underrepresented on chromatin. H3K56me3 is a novel heterochromatin mark, since it is enriched at pericentromeres but not telomeres and is thereby similar, but not identical, to the localization of H3K9me3 and H4K20me3. Possibly due to H3 sequence similarities, Suv39h enzymes, responsible for trimethylation of H3K9, also affect methylation of H3K56. Similarly, we demonstrate that trimethylation of H3K56 is removed by members of the JMJD2 family of demethylases that also target H3K9me3. Furthermore, we identify and characterize mouse mJmjd2E and its human homolog hKDM4L as novel, functionally active enzymes that catalyze the removal of two methyl groups from trimethylated H3K9 and K56. H3K56me3 is also found in C. elegans, where it co-localizes with H3K9me3 in most, but not all, tissues. Taken together, our findings raise interesting questions regarding how methylation of H3K9 and H3K56 is regulated in different organisms and their functional roles in heterochromatin formation and/or maintenance

Announcing the 2019 Processes Travel Awards for Post-Doctoral Fellows and Ph.D. Students

Note: In lieu of an abstract, this is an excerpt from the first page. In order to support the development of early career researchers involved in chemical and biological process/systems engineering, Processes launched the second Travel Awards for Post-doctoral Fellows and Ph.D. Students. We received a large number of highly meritorious applications from all over the world. On behalf of the Editors of Processes, we are pleased to announce the winners of Processes Travel Awards for 2019

Real-World Evidence Study on the Long-Term Safety of Everolimus in Patients With Tuberous Sclerosis Complex: Final Analysis Results

Everolimus; Post-authorization safety study; Tuberous sclerosis complexEverolimus; Estudio de seguridad posautorización; Complejo de esclerosis tuberosaEverolimus; Estudi de seguretat posterior a l'autorització; Complex d'esclerosi tuberosaThe TuberOus SClerosis registry to increase disease Awareness (TOSCA) Post-Authorization Safety Study (PASS) was a non-interventional, multicenter, safety substudy that assessed the long-term safety of everolimus in patients with tuberous sclerosis complex (TSC) receiving everolimus for its licensed indications in the European Union (EU). This substudy also aimed to address TSC-associated neuropsychiatric disorders (TAND), sexual development, and male infertility. Eligible patients were enrolled from 39 sites across 11 countries in the EU. Outcomes of interest included the incidence of adverse events (AEs), serious adverse events (SAEs), treatment-related AEs (TRAEs), AEs leading to everolimus discontinuation, AEs of special interest (AESIs), the observed relationship between everolimus blood levels and incidence of AESIs, TAND, and reproductive clinical features. Herein, we present the final analysis results from this substudy (data cutoff date: 22 January 2020). At data cutoff, 179 patients were enrolled (female, 59.2%; age ≥18 years, 65.9%), of which the majority completed the study (76%). Overall, 121 patients (67.6%) had AEs regardless of causality. The most frequent TRAEs (≥5%) were stomatitis (7.8%), aphthous ulcer (6.7%), and hypercholesterolemia (6.1%). The most common treatment-related SAEs (>1%) were pneumonia (3.4%), influenza, pyelonephritis, aphthous ulcer, stomatitis, dyslipidemia, and hypercholesterolemia (1.1% each). Ten patients (5.6%) reported AEs leading to everolimus discontinuation. The common psychiatric disorders (N = 179) were autism spectrum disorder (21.8%), anxiety disorder (12.8%), “other” psychiatric disorders (8.9%), attention-deficit hyperactivity disorder, and depressive disorder (7.8% each). Of 179 patients, 88 (49.2%) had ≥1 behavioral problem. Of these (n = 88), the most common (>20%) were sleep difficulties (47.7%), anxiety (43.2%), mood swings (37.5%), depression mood (35.2%), impulsivity (30.7%), severe aggression (23.9%), and overactivity (22.7%). Of 179 patients, four (2.2%) reported abnormal puberty onset, and three (1.7%) reported other reproductive disorders. Of 106 females, 23 (21.7%) reported menstrual cycle disorders and 10 (9.4%) reported amenorrhea. Available data did not show delays in sexual maturation or an association between sexual development and infertility. The results demonstrate that everolimus has a manageable long-term safety profile in the TSC treatment setting. No new safety signals emerged. This substudy also contributed to the mapping of TAND and reproductive clinical features in patients with TSC.This study was funded by Novartis Pharmaceuticals Corporation

How space design and technology can support the Pharmacy Practice Model Initiative through interprofessional collaboration

Purpose: The Pharmacy Practice Model Initiative (PPMI) calls pharmacists to more direct patient care and increased responsibility for medication-related outcomes, as a means of achieving greater safety, improving outcomes and reducing costs. This article acknowledges the value of interprofessional collaboration to the PPMI and identifies the implications of the Initiative for space design and technology, both of which stand to help the Initiative gather additional support. Summary: The profession of pharmacy has for some time now become increasingly vocal about its desire to take on greater responsibility for patient outcomes. With drug costs representing the largest portion of a hospital’s pharmacy budget and reimbursements becoming more contingent on readmission avoidance, the pharmacy’s influence on a hospital’s bottom line is significant. More importantly, study after study is showing that with greater pharmacist intervention, patient outcomes improve. This article addresses the ways in which developments in the fields of technology and facility design can assist in the deployment of the PPMI. Conclusion: As the PPMI achieves a critical level of support from inside and outside the pharmacy, and more empirical research emerges regarding the improved outcomes and cost savings of increasing the roles of both clinical pharmacists and pharmacy technicians, the industry sectors of healthcare technology and healthcare design stand ready to assist in the execution of this new model. By encouraging pharmacists, doctors and nurses to work together – and all caregivers to work with facility designers, biomedical engineers and IT specialists, there is the increased likelihood of these fields turning to each other to problem-solve together, all for the ultimate benefit to patients and their families

Nutrient Removal Performance on Domestic Wastewater Treatment Plants (Full Scale System) between Tropical Humid and Cold Climates

Two full scale systems of oxidation ditches for domestic wastewater treatment plants (WWTP) were used as study sites: Phuket Province, southern Thailand (representative of tropical humid climates) and Plum Creek, Castle Rock, Colorado, USA (representative of cold climates). The treatment systems at both sites were designed for biological nutrient removal (BNR) from extended activated sludge. Nitrogen is removed by nitrification-denitrification processes. The solid retention time (SRT) for both treatment plants was ≥ 10 d as recommended by theory for complete nitrification in activated sludge wastewater treatment plants. Influents and effluents from these sites were compared in respect to flow rate, biochemical oxygen demand (BOD), organic nitrogen, ammonium, nitrate, total nitrogen, and phosphorus concentrations. At both sites, nutrient removal reached more than 75 % because there was sufficient carbon for denitrifying and phosphate accumulating organisms. Furthermore, low dissolved oxygen concentration, long SRT, and high temperature could be key factors to promote activity of some groups of bacteria in consuming organic matter and nutrients in wastewater in warm climates. For this reason, plant design and operating procedures for wastewater treatment in cold climates might not be always be applicable to warm climates

Characterization of the manganese sites in manganese redox enzymes: Catalase and superoxide dismutase.

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/30701/1/0000346.pd

Health-related quality of life in young adults with symptoms of constipation continuing from childhood into adulthood

<p>Abstract</p> <p>Background</p> <p>Children with functional constipation report impaired Health-related Quality of Life (HRQoL) in relation to physical complaints and long duration of symptoms. In about one third of children with constipation, symptoms continue into adulthood. Knowledge on HRQoL in adults with constipation persisting from childhood is lacking.</p> <p>Objectives</p> <p>To assess HRQoL in adults with constipation from early childhood in comparison to that of their peers. Furthermore to gain insight into the specific social consequences related to continuing symptoms of constipation and/or fecal incontinence at adult age.</p> <p>Methods</p> <p>One HRQoL questionnaire and one self-developed questionnaire focusing on specific consequences of symptoms of constipation continuing into adulthood were administrated to 182 adults with a history of childhood constipation. Successful clinical outcome was defined as a defecation frequency three or more times per week with less than two episodes of fecal incontinence per month, irrespective of laxative use. HRQoL of both adults with unsuccessful and successful clinical outcome were compared to a control group of 361 peers from the general Dutch population.</p> <p>Results</p> <p>No differences in HRQoL were found between the whole study population and healthy peers, nor between adults with successful clinical outcome (n = 139) and the control group. Adults with an unsuccessful clinical outcome (n = 43) reported significantly lower HRQoL compared to the control group with respect to scores on bodily pain (mean ± SD 77.4 ± 19.6 versus 85.7 ± 19.5, p = 0.01) and general health (67.6 ± 18.8 versus 74.0 ± 18.1, p = 0.04). Adults with an unsuccessful clinical outcome reported difficulties with social contact and intimacy (20% and 12.5%, respectively), related to their current symptoms. Current therapy in these adults was more often self-administered treatment (e.g. diet modifications) (60.4%) than laxatives (20.9%).</p> <p>Conclusion</p> <p>Overall, young adults with constipation in childhood report a good quality of life, as HRQoL of adults with successful clinical outcome was comparable to that of their peers. However, when childhood constipation continues into adulthood, it influences HRQoL negatively with social consequences in 20% of these adults.</p

16p11.2 600 kb Duplications confer risk for typical and atypical Rolandic epilepsy

Rolandic epilepsy (RE) is the most common idiopathic focal childhood epilepsy. Its molecular basis is largely unknown and a complex genetic etiology is assumed in the majority of affected individuals. The present study tested whether six large recurrent copy number variants at 1q21, 15q11.2, 15q13.3, 16p11.2, 16p13.11 and 22q11.2 previously associated with neurodevelopmental disorders also increase risk of RE. Our association analyses revealed a significant excess of the 600 kb genomic duplication at the 16p11.2 locus (chr16: 29.5-30.1 Mb) in 393 unrelated patients with typical (n = 339) and atypical (ARE; n = 54) RE compared with the prevalence in 65 046 European population controls (5/393 cases versus 32/65 046 controls; Fisher's exact test P = 2.83 × 10−6, odds ratio = 26.2, 95% confidence interval: 7.9-68.2). In contrast, the 16p11.2 duplication was not detected in 1738 European epilepsy patients with either temporal lobe epilepsy (n = 330) and genetic generalized epilepsies (n = 1408), suggesting a selective enrichment of the 16p11.2 duplication in idiopathic focal childhood epilepsies (Fisher's exact test P = 2.1 × 10−4). In a subsequent screen among children carrying the 16p11.2 600 kb rearrangement we identified three patients with RE-spectrum epilepsies in 117 duplication carriers (2.6%) but none in 202 carriers of the reciprocal deletion. Our results suggest that the 16p11.2 duplication represents a significant genetic risk factor for typical and atypical R